Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TMER1i
- Development stage
- Unknown
- Lead developer
- Crossignal Therapeutics
01
Overview
TMER1i: sourced facts only. name: "TMER1i potently blocks GPR35 in Hippo suppression and YAP activation." [DOI:10.1158/1538-7445.am2024-lb426]; target: "TMER1i potently blocks GPR35 in Hippo suppression and YAP activation." [DOI:10.1158/1538-7445.am2024-lb426]; developer: "1Crossignal Therapeutics, Inc, La Jolla, CA." [DOI:10.1158/1538-7445.am2024-lb426]; stage: "When dosed in human-PBMC reconstituted NCG mice bearing HT29 tumors, TMER1i dose-dependently increased the infiltration of human CD8 T cells within tumors in a statistically significant manner, and a trending lower Treg cell infiltration, accompanied by a tumor growth inhibition." [DOI:10.1158/1538-7445.am2024-lb426]
02
Targets
GPR35 (G-protein Coupled Receptor 35)
Beyond the preview
Go deeper on TMER1i.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TMER1i.